产品
编 号：F527852
分子式：C48H55N6Na3O8.2.5H2O
分子量：957.99
分子式：C48H55N6Na3O8.2.5H2O
分子量：957.99
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
结构图
CAS No: 936623-90-4
产品详情
生物活性：
Sacubitril/Valsartan (LCZ696), comprised Valsartan and Sacubitril (AHU377) in 1:1 molar ratio, is a first-in-class, orally bioavailable, and dual-acting angiotensin receptor-neprilysin (ARN) inhibitor for hypertension and heart failure. Sacubitril/Valsartan ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis.
体内研究：
Sacubitril/Valsartan (LCZ696; perorally; 68 mg/kg for 4 weeks) significantly exhibits small weights and reduces interstitial fibrosis both in the noninfarct zone and peri-infarct zone.Animal Model:Adult 6- to 8-week-old male Sprague-Dawley rats (220-250 g body weight)
Dosage:68 mg/kg
Administration:Perorally; for 4 weeks
Result:Exhibited small weights and reduced interstitial fibrosis both in the noninfarct zone and peri-infarct zone.
体外研究：
Sacubitril/Valsartan (LCZ696; 1-30 μM; 0.5?hours) inhibits HG-treated H9C2 cells apoptosis in an experimental model of Diabetic cardiomyopathy (DCM). Sacubitril/Valsartan (1-30 μM; 0.5?hours) increases the expression level of cleaved caspase-3 and the ratio of Bax/Bcl-2 in HG-treated H9C2 cells.
Sacubitril/Valsartan (LCZ696), comprised Valsartan and Sacubitril (AHU377) in 1:1 molar ratio, is a first-in-class, orally bioavailable, and dual-acting angiotensin receptor-neprilysin (ARN) inhibitor for hypertension and heart failure. Sacubitril/Valsartan ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis.
体内研究：
Sacubitril/Valsartan (LCZ696; perorally; 68 mg/kg for 4 weeks) significantly exhibits small weights and reduces interstitial fibrosis both in the noninfarct zone and peri-infarct zone.Animal Model:Adult 6- to 8-week-old male Sprague-Dawley rats (220-250 g body weight)
Dosage:68 mg/kg
Administration:Perorally; for 4 weeks
Result:Exhibited small weights and reduced interstitial fibrosis both in the noninfarct zone and peri-infarct zone.
体外研究：
Sacubitril/Valsartan (LCZ696; 1-30 μM; 0.5?hours) inhibits HG-treated H9C2 cells apoptosis in an experimental model of Diabetic cardiomyopathy (DCM). Sacubitril/Valsartan (1-30 μM; 0.5?hours) increases the expression level of cleaved caspase-3 and the ratio of Bax/Bcl-2 in HG-treated H9C2 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备